Osprey Technology Acquisition Corp. (NYSE:SFTW) announced in an 8-K filing today that its shareholders approved its combination with satellite imaging company BlackSky Holdings, Inc. in a meeting held earlier today.
The filing disclosed that 21,375,376 shares were redeemed for a pro rata portion of the funds in the trust account at approximately $10.05 per share. As a result, approximately $214,906,385.05 million, or 65.9%, will be removed from the trust to pay the shareholders. SFTW saw high volume today with 3,082,404 shares traded throughout the day, representing approximately $30 million+ or 1/3 of the public float. SFTW closed today at $10.40.
Holders of 26,572,450 shares of SFTW’s stock were present at the meeting, representing 67.22% of the voting power. The business combination was overwhelmingly approved as it received 26,398,002 votes in favor of the proposal.
Although the 8-K did not give an exact timeline on the closing of the transaction, Osprey Technology expects it to be completely promptly. The company is expected to remain listed on the New York Stock Exchange with its common stock and warrants trading under the new ticker symbol “BKSY” and “BKSY.W” respectively.
The parties initially announced their $1.106 billion deal on February 18. Herndon V.A. based BlackSky is a a real-time Earth observation company leveraging the innovative performance and economics of small satellite constellations to deliver high revisit global monitoring solutions.
Just yesterday, BlackSky was awarded a five year contract by the National Geospatial-Intelligence Agency valued at $30 million.
ADVISORS
- Credit Suisse Securities (USA) LLC is acting as lead financial advisor and as capital markets advisor to BlackSky
- Credit Suisse Securities (USA) LLC acted as lead placement agent and Moelis & Company LLC also acted as placement agents in connection with the PIPE offering
- Moelis & Company LLC is acting as lead financial advisor and Union Square Advisors LLC is acting as capital markets and strategic advisor to Osprey
- PJT Partners LP is one of BlackSky’s financial advisors and a placement agent with respect to this transaction
- Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal advisor to BlackSky
- Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to Osprey
- Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as legal advisor to Credit Suisse Securities (USA) LLC
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...